Cargando…
The E3 ubiquitin ligase HUWE1 acts through the N‐Myc‐DLL1‐NOTCH1 signaling axis to suppress glioblastoma progression
BACKGROUND: Elucidation of the post‐transcriptional modification has led to novel strategies to treat intractable tumors, especially glioblastoma (GBM). The ubiquitin‐proteasome system (UPS) mediates a reversible, stringent and stepwise post‐translational modification which is closely associated wit...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456703/ https://www.ncbi.nlm.nih.gov/pubmed/35848447 http://dx.doi.org/10.1002/cac2.12334 |
_version_ | 1784785882787610624 |
---|---|
author | Yuan, Ye Wang, Li‐Hong Zhao, Xian‐Xian Wang, Jiao Zhang, Meng‐Si Ma, Qing‐Hua Wei, Sen Yan, Ze‐Xuan Cheng, Yue Chen, Xiao‐Qing Zou, Hong‐Bo Ge, Jia Wang, Yan Zhang, Xia Cui, You‐Hong Luo, Tao Bian, Xiu‐Wu |
author_facet | Yuan, Ye Wang, Li‐Hong Zhao, Xian‐Xian Wang, Jiao Zhang, Meng‐Si Ma, Qing‐Hua Wei, Sen Yan, Ze‐Xuan Cheng, Yue Chen, Xiao‐Qing Zou, Hong‐Bo Ge, Jia Wang, Yan Zhang, Xia Cui, You‐Hong Luo, Tao Bian, Xiu‐Wu |
author_sort | Yuan, Ye |
collection | PubMed |
description | BACKGROUND: Elucidation of the post‐transcriptional modification has led to novel strategies to treat intractable tumors, especially glioblastoma (GBM). The ubiquitin‐proteasome system (UPS) mediates a reversible, stringent and stepwise post‐translational modification which is closely associated with malignant processes of GBM. To this end, developing novel therapeutic approaches to target the UPS may contribute to the treatment of this disease. This study aimed to screen the vital and aberrantly regulated component of the UPS in GBM. Based on the molecular identification, functional characterization, and mechanism investigation, we sought to elaborate a novel therapeutic strategy to target this vital factor to combat GBM. METHODS: We combined glioma datasets and human patient samples to screen and identify aberrantly regulated E3 ubiquitin ligase. Multidimensional database analysis and molecular and functional experiments in vivo and in vitro were used to evaluate the roles of HECT, UBA and WWE domain‐containing E3 ubiquitin ligase 1 (HUWE1) in GBM. dCas9 synergistic activation mediator system and recombinant adeno‐associated virus (rAAV) were used to endogenously overexpress full‐length HUWE1 in vitro and in glioma orthotopic xenografts. RESULTS: Low expression of HUWE1 was closely associated with worse prognosis of GBM patients. The ubiquitination and subsequent degradation of N‐Myc mediated by HUWE1, leading to the inactivation of downstream Delta‐like 1 (DLL1)‐NOTCH1 signaling pathways, inhibited the proliferation, invasion, and migration of GBM cells in vitro and in vivo. A rAAV dual‐vector system for packaging and delivery of dCas9‐VP64 was used to augment endogenous HUWE1 expression in vivo and showed an antitumor activity in glioma orthotopic xenografts. CONCLUSIONS: The E3 ubiquitin ligase HUWE1 acts through the N‐Myc‐DLL1‐NOTCH1 signaling axis to suppress GBM progression. Antitumor activity of rAAV dual‐vector delivering dCas9‐HUWE1 system uncovers a promising therapeutic strategy for GBM. |
format | Online Article Text |
id | pubmed-9456703 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94567032022-09-12 The E3 ubiquitin ligase HUWE1 acts through the N‐Myc‐DLL1‐NOTCH1 signaling axis to suppress glioblastoma progression Yuan, Ye Wang, Li‐Hong Zhao, Xian‐Xian Wang, Jiao Zhang, Meng‐Si Ma, Qing‐Hua Wei, Sen Yan, Ze‐Xuan Cheng, Yue Chen, Xiao‐Qing Zou, Hong‐Bo Ge, Jia Wang, Yan Zhang, Xia Cui, You‐Hong Luo, Tao Bian, Xiu‐Wu Cancer Commun (Lond) Original Articles BACKGROUND: Elucidation of the post‐transcriptional modification has led to novel strategies to treat intractable tumors, especially glioblastoma (GBM). The ubiquitin‐proteasome system (UPS) mediates a reversible, stringent and stepwise post‐translational modification which is closely associated with malignant processes of GBM. To this end, developing novel therapeutic approaches to target the UPS may contribute to the treatment of this disease. This study aimed to screen the vital and aberrantly regulated component of the UPS in GBM. Based on the molecular identification, functional characterization, and mechanism investigation, we sought to elaborate a novel therapeutic strategy to target this vital factor to combat GBM. METHODS: We combined glioma datasets and human patient samples to screen and identify aberrantly regulated E3 ubiquitin ligase. Multidimensional database analysis and molecular and functional experiments in vivo and in vitro were used to evaluate the roles of HECT, UBA and WWE domain‐containing E3 ubiquitin ligase 1 (HUWE1) in GBM. dCas9 synergistic activation mediator system and recombinant adeno‐associated virus (rAAV) were used to endogenously overexpress full‐length HUWE1 in vitro and in glioma orthotopic xenografts. RESULTS: Low expression of HUWE1 was closely associated with worse prognosis of GBM patients. The ubiquitination and subsequent degradation of N‐Myc mediated by HUWE1, leading to the inactivation of downstream Delta‐like 1 (DLL1)‐NOTCH1 signaling pathways, inhibited the proliferation, invasion, and migration of GBM cells in vitro and in vivo. A rAAV dual‐vector system for packaging and delivery of dCas9‐VP64 was used to augment endogenous HUWE1 expression in vivo and showed an antitumor activity in glioma orthotopic xenografts. CONCLUSIONS: The E3 ubiquitin ligase HUWE1 acts through the N‐Myc‐DLL1‐NOTCH1 signaling axis to suppress GBM progression. Antitumor activity of rAAV dual‐vector delivering dCas9‐HUWE1 system uncovers a promising therapeutic strategy for GBM. John Wiley and Sons Inc. 2022-07-18 /pmc/articles/PMC9456703/ /pubmed/35848447 http://dx.doi.org/10.1002/cac2.12334 Text en © 2022 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Yuan, Ye Wang, Li‐Hong Zhao, Xian‐Xian Wang, Jiao Zhang, Meng‐Si Ma, Qing‐Hua Wei, Sen Yan, Ze‐Xuan Cheng, Yue Chen, Xiao‐Qing Zou, Hong‐Bo Ge, Jia Wang, Yan Zhang, Xia Cui, You‐Hong Luo, Tao Bian, Xiu‐Wu The E3 ubiquitin ligase HUWE1 acts through the N‐Myc‐DLL1‐NOTCH1 signaling axis to suppress glioblastoma progression |
title | The E3 ubiquitin ligase HUWE1 acts through the N‐Myc‐DLL1‐NOTCH1 signaling axis to suppress glioblastoma progression |
title_full | The E3 ubiquitin ligase HUWE1 acts through the N‐Myc‐DLL1‐NOTCH1 signaling axis to suppress glioblastoma progression |
title_fullStr | The E3 ubiquitin ligase HUWE1 acts through the N‐Myc‐DLL1‐NOTCH1 signaling axis to suppress glioblastoma progression |
title_full_unstemmed | The E3 ubiquitin ligase HUWE1 acts through the N‐Myc‐DLL1‐NOTCH1 signaling axis to suppress glioblastoma progression |
title_short | The E3 ubiquitin ligase HUWE1 acts through the N‐Myc‐DLL1‐NOTCH1 signaling axis to suppress glioblastoma progression |
title_sort | e3 ubiquitin ligase huwe1 acts through the n‐myc‐dll1‐notch1 signaling axis to suppress glioblastoma progression |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456703/ https://www.ncbi.nlm.nih.gov/pubmed/35848447 http://dx.doi.org/10.1002/cac2.12334 |
work_keys_str_mv | AT yuanye thee3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT wanglihong thee3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT zhaoxianxian thee3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT wangjiao thee3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT zhangmengsi thee3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT maqinghua thee3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT weisen thee3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT yanzexuan thee3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT chengyue thee3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT chenxiaoqing thee3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT zouhongbo thee3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT gejia thee3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT wangyan thee3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT zhangxia thee3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT cuiyouhong thee3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT luotao thee3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT bianxiuwu thee3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT yuanye e3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT wanglihong e3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT zhaoxianxian e3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT wangjiao e3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT zhangmengsi e3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT maqinghua e3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT weisen e3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT yanzexuan e3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT chengyue e3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT chenxiaoqing e3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT zouhongbo e3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT gejia e3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT wangyan e3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT zhangxia e3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT cuiyouhong e3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT luotao e3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression AT bianxiuwu e3ubiquitinligasehuwe1actsthroughthenmycdll1notch1signalingaxistosuppressglioblastomaprogression |